Resveratrol and its analogues have drawn scientific interest for their potential effects on metabolic syndrome, a cluster of conditions including obesity, insulin resistance, dyslipidemia, and hypertension. Preclinical studies in animal models and cell cultures have shown that resveratrol analogues can improve insulin sensitivity, reduce inflammation, and modulate lipid metabolism, primarily through the activation of SIRT1 and AMP-activated protein kinase (AMPK) pathways. These mechanisms may counteract some of the underlying pathologies of metabolic syndrome. Small-scale human studies and pilot clinical trials suggest possible benefits in improving insulin resistance and certain lipid parameters, but the results are inconsistent and often limited by sample size, short duration, or the use of surrogate endpoints rather than hard clinical outcomes. Systematic reviews and meta-analyses generally conclude that, while there is some evidence for beneficial metabolic effects of resveratrol and closely related analogues, the clinical evidence remains insufficient and more robust, large-scale trials are needed. Thus, the use of resveratrol analogues for metabolic syndrome is supported by some scientific evidence, but it is not yet considered a standard or highly substantiated intervention in clinical practice.